MK7123-034 : A Phase II Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced/Metastatic Solid Tumors

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

18+Age Over 18

Advanced CancersCancer LocationMulti-Cancer
Trial

Systemic therapy | Bowel (colorectum),Lung,Urinary systemColon,Colorectum,Non-Small Cell Lung Cancer,Prostate,Rectum

Trial Overview Read MoreRead more

This phase II trial is testing the effectiveness of an oral drug (MK-7123 / Navarixin) when given in combination with an immunotherapy treatment (Pembrolizumab) in patients with non-small cell (NSC) lung cancer, castration resistant prostate cancer or microsatellite stable colorectal cancer.
 

This trial is treating multiple types of cancer including non-small cell (NSC) lung cancer, castration resistant prostate cancer or microsatellite stable colorectal cancer.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Phase II Study of Navarixin (MK-7123) in Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced/Metastatic Solid Tumors

Commercial Sponsor

Merck

Summary

The purpose of this study is to assess the efficacy and safety of navarixin (MK-7123) in combination with pembrolizumab (MK-3475) in adults with one of three types of solid tumors: Programmed Death-Ligand 1 (PD-L1) positive refractory non-small cell lung cancer (NSCLC), castration resistant prostate cancer (CRPC) or microsatellite stable (MSS) colorectal cancer (CRC). Participants will be randomized into one of two arms of the trial. In Experimental Arm A, patients will receive navarixin Dose A via oral capsules once daily PLUS pembrolizumab 200 mg via intravenous infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years). In Experimental Arm B, patients will receive Participants receive navarixin Dose B via oral capsules once daily PLUS pembrolizumab 200 mg via intravenous infusion on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years).

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Ms Marian Lieschke
marian.lieschke@petermac.org
03 8559 7140

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next